Vaccine adjuvant formulation: a relatively neglected field that is crucial to vaccine success.
This 3-day conference, with a focus on formulation, is part of a series of conferences organized by Meetings Management on different aspects of vaccine adjuvants. The previous Modern Vaccine/Adjuvants Formulation took place in Prague in 2004 and it was interesting to observe what has changed and what since then remains the same.
Davies
Gwyn
G
European Adjuvant Advisory Committee, Cardiac and Vascular Sciences, St George's University of London, UK. jdavies@sgul.ac.uk
D000276:Adjuvants, Immunologic / Q000138:chemical synthesis / Q000627:therapeutic use*; D000818:Animals; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic / Q000639:trends; D006801:Humans; D014612:Vaccines / Q000138:chemical synthesis* / Q000627:therapeutic use*; D019444:Vaccines, DNA / Q000138:chemical synthesis / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D014612:Vaccines; D019444:Vaccines, DNA